普莱柯：截至目前，公司已获得国家新兽药注册证书81项，累计申请发明专利600余项

Core Viewpoint - The company, Pulaike (603566.SH), emphasizes its research and development capabilities in the veterinary medicine sector, despite concerns about its lag in vaccine development for major diseases like African swine fever compared to competitors. Group 1: R&D Infrastructure - The company has established multiple national and provincial-level innovation platforms, including the National Engineering Research Center for Veterinary Drugs and the National Key Laboratory for Animal Infectious Disease Diagnosis and Vaccine Development [1] - It has built a biosafety level 3 laboratory that is operational and has received approval for activities involving certain pathogenic microorganisms [1] Group 2: Technological Capabilities - The company has developed a comprehensive set of technical platforms over the years, including reverse genetics, prokaryotic and eukaryotic expression technologies, multivalent vaccine technology, high-density fermentation technology, and antigen concentration and purification technology [1] - These platforms enable the company to develop a series of genetically engineered vaccines [1] Group 3: Innovation and Achievements - The company has produced several innovative products that fill gaps in both international and domestic markets, including various inactivated vaccines for poultry and swine [1] - As of now, the company has obtained 81 national new veterinary drug registration certificates, filed over 600 invention patent applications, and received 340 invention patent grants, along with three second-class National Science and Technology Progress Awards [1]